Impact of Autologous Stem Cell Transplantation on Primary Central Nervous System Lymphoma in First-Line and Relapse Settings: A Retrospective Study in China

Jing Liu; Haitao Wang; Xiaohong Li; Yamei Wu; Yuanyuan Ma; Zhenyang Gu; Fei Li; Meng Li; Jiayuan Guo; Yu Zhao; Quanshun Wang; Jian Bo; Wenrong Huang; Liping Dou; Yuanbo Liu; Daihong Liu; Xiaoxiong Wu; Chunji Gao

doi:10.12659/AOT.938467

03 January 2023 : Original article

Impact of Autologous Stem Cell Transplantation on Primary Central Nervous System Lymphoma in First-Line and Relapse Settings: A Retrospective Study in China

Jing Liu^1BCDEF*, Haitao Wang^1BCDF, Xiaohong Li^1B, Yamei Wu^1B, Yuanyuan Ma^1B, Zhenyang Gu^1B, Fei Li^1B, Meng Li^1BD, Jiayuan Guo^2B, Yu Zhao^1B, Quanshun Wang^1B, Jian Bo^1B, Wenrong Huang^3B, Liping Dou^1BD, Yuanbo Liu^4AEF, Daihong Liu^1BD, Xiaoxiong Wu^1ADF, Chunji Gao^1ADEFG

DOI: 10.12659/AOT.938467

Ann Transplant 2023; 28:e938467

Authors information Article notes Copyright and License information

Background Material and Methods Results Discussion Conclusions References

Related articles Order reprints Share article Share by email

View HTML version

Table 3 ASCT as salvage treatment for relapsed/refractory patients with PCNSL.

Sex/age	Patient	ECOG	Number of recurrences before ASCT	Conditioning regimen	Pre-ASCT	Post-ASCT	Timing of WBRT	Neutrophil/platelet engraftment time (days)
M/61	11	2	1	TBC-like	CR2	CR	–	10/12
M/56	12	2	1	Modified TBC	CR2	CR	–	13/15
M/50	13	1	1	Modified TBC	CR2	CR	Before ASCT	13/13
M/22	14	0	1	Modified TBC	CR2	CR	–	31/35
M/44	15	3	2	Modified TBC	PR	PR	Before ASCT	15/28
F/49	16	2	4	Modified TBC	PR	CR	Before ASCT	16/50
M/59	17	3	3	Modified TBC	CRu3	PD	–	15/−
M/47	18	3	0	Modified TBC	PR	CRu	Before ASCT	13/13
F/53	19	1	0	Modified TBC	CRu	CR	Before ASCT	12/17
M/40	20	2	1	TBC-like	CR	CR	Before ASCT	19/108

M/61	11	Haematologic toxicities, fever, hypokalaemia, gastrointestinal toxicities			–		15.0	15.0	A Wo D
M/56	12	Haematologic toxicities, fever, rashgastrointestinal toxicities, mucositis			–		9.5	9.5	A Wo D
M/50	13	Haematologic toxicities, fever, gastrointestinal toxicities			Leukoencephalopathy		27.0	27.0	A Wo D
M/22	14	Haematologic toxicities, haemorrhagic cystitis			–		33.2	33.2	A Wo D
M/44	15	Haematologic toxicities, gastrointestinal toxicities			Alalia, Unresponsive		4.5	4.5	TRD
F/49	16	Haematologic toxicities, gastrointestinal toxicities, infection, mucositis			–		12.7	12.7	A Wo D
M/59	17	Haematologic toxicities, gastrointestinal toxicities, pneumonia, encephalitis			–		0.53	0.53	TRD
M/47	18	Haematologic toxicities, gastrointestinal toxicities, infection, hepatotoxicity			Alalia		19.2	23.9	DOD
F/53	19	Haematologic toxicities, gastrointestinal toxicities, pneumonia			–		1.8	1.8	A Wo D
M/40	20	Haematologic toxicities, gastrointestinal toxicities, infection, rash, hypokalaemia, mucositis			–		7.7	7.7	A Wo D
TBC – thiotepa + busulfan + cyclophosphamide; Modified TBC – TBC + cladribine + etoposide + cytarabine; CR – complete remission; Cru – unconfirmed CR; HDC – high-dose chemotherapy; PFS – progression-free survival; OS – overall survival; A Wo D – alive without disease; DOD – dead of disease; TRD – treatment-related death. OS1 and PFS1 were measured from the day of transplantation.

Back to the Article

Impact of Autologous Stem Cell Transplantation on Primary Central Nervous System Lymphoma in First-Line and Relapse Settings: A Retrospective Study in China

Your Privacy